Patient and Provider Glucose Reporting Preferences Ambulatory Glucose Profile (AGP)

Not Applicable

Completed

Conditions: Type 1 Diabetes

Interventions: Device: Continuous Glucose Monitor
Other: Clinician
Device: Self Monitoring Blood Glucose

Registration Number: NCT02074384

Lead Sponsor: HealthPartners Institute

Brief Summary: International Diabetes Center (IDC) proposes a preference and usability study of glucose data acquisition and reporting, evaluating streamlined standardized cloud-based glucose reporting including work flow as well as patient and clinician preference at Type 1 Diabetes (T1D) Exchange sites to enhance standard Ambulatory Glucose Profile (AGP) reporting. This phase 2 project assesses the efficacy of standardized glucose data report generation and preferred report presentation format; both are necessary to increase use of continuous glucose monitoring (CGM) data to improve care processes and outcomes for Type 1 diabetes.

Detailed Description: Patient participation in diabetes treatment has relied upon episodic self-monitoring of blood glucose (SMBG). SMBG assists patients and clinicians with adjustments of insulin, identification of hypoglycemia, nutritional intake and activity in order to optimize diabetes control. SMBG however is subject to bias dependent upon the testing frequency and timing. In contrast, continuous glucose monitoring (CGM) systems capture continuous 24-hour glucose data uninterrupted and unbiased. It provides valuable information about daily/nightly alterations in glucose patterns. Unfortunately SMBG, CGM and insulin pump devices have proprietary software with unique data standards, acquisition methods, reports, and graphic displays. These differences make evaluation and comparison of SMBG or CGM data difficult for clinicians and patients. IDC created an Ambulatory Glucose Profile (AGP) report to reduce challenges of device specific reports through a standardized report which is produced from any device with streamlined graphic displays of glucose trends.

The phase 1 project (2012), gathered expert stakeholders (clinical, research, industry, patients) who validated data standards and recommended changes to the CGM-AGP reports. These changes are now integrated into a secure cloud-based infrastructure for AGP reporting.

Phase 2 of this project is a usability and preference study of glucose reporting systems. It will include an in depth study of 6 T1D Ex clinical sites. The T1D Exchange Clinic Network was formed to support the development of a large registry of adults and children with type 1 diabetes for the purpose of conducting multiple studies proposed by T1D Exchange investigators, and other researchers, patients, and companies.

The 6 sites will be selected for an in-depth study utilizing middleware data collection services (Diasend or SweetSpot) to facilitate efficient collection of data from diverse devices. These middleware solutions integrate with the captūrAGP system to automatically produce an AGP report. These sites will test the feasibility of AGP cloud reporting while collecting patient and clinician opinions on report preference. All 6 sites participating in phase 2 will collect patient and clinician preference measures. Two study sites will undergo time in motion (TIM) measurement and workflow mapping of current process. This TIM sub-study includes workflow mapping of current and cloud-based processes utilizing Toyota Lean (Kaizen) methodology. Sites 3 - 6 will receive enhanced designs through the adaptive trial method with learnings applied from sites 1 and 2.

A key deliverable of this study is patient and clinician insight into their utilization of CGM reporting technologies. Recognizing that adoption of technology is often stymied by time constraints, report reliability and ease of interpretation, these variables will be examined. The goal of phase 2 is to analyze the viability of standard reporting and to evaluate preference (patient and clinicians) for and perceived value of different types of glucose pattern reports (AGP vs. device) including clinical practice time saved.

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 161

Inclusion Criteria

Type 1 Diabetics

Exclusion Criteria

Less than the age of 7
Non-English Speaker

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Continuous Glucose Monitoring	Continuous Glucose Monitor	Participants will wear Continuous Glucose Monitoring for two weeks.
Clinicians	Clinician	Clinicians completing study visits.
Self Monitoring Blood Glucose	Self Monitoring Blood Glucose	Participants will self test for two weeks.

Primary Outcome Measures

Name	Time	Method
Portion of Study Participants Reporting Greater Utility From AGP vs. Traditional Glucose Data Reports	At the end of the two week SMBG or CGM period	Patients will use either SMBG or CGM for a two week period following their screening visit. At the end of the two week period they will return to the study site to download their device and have an AGP report printed. They will then complete a preference and utility survey.

Secondary Outcome Measures

Name	Time	Method

Trial Locations

Locations (7): St. Vincent's
🇺🇸
Billings, Montana, United States
Eda Cengiz
🇺🇸
New Haven, Connecticut, United States
Larry Deeb
🇺🇸
Tallahassee, Florida, United States
Park Nicollet International Diabetes Center
🇺🇸
Minneapolis, Minnesota, United States
Henry Ford
🇺🇸
Detroit, Michigan, United States
The Diabetes Center, PLLC
🇺🇸
Ocean Springs, Mississippi, United States
Columbia University
🇺🇸
New York City, New York, United States